Biology of Blood and Marrow Transplantation
Volume 12, Issue 6 , Pages 688-690 , June 2006

Target Populations in Allogeneic Hematopoietic Cell Transplantation for Autoimmune Diseases— A Workshop Accompanying: Cellular Therapy for Treatment of Autoimmune Diseases, Basic Science and Clinical Studies, Including New Developments in Hematopoietic and Mesenchymal Stem Cell Therapy1

  • Linda M. Griffith, MD, PhD

      Affiliations

    • Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
    • Corresponding Author InformationCorrespondence and reprint requests: Linda M. Griffith, MD, PhD, Division of Allergy, Immunology and Transplantation National Institute of Allergy and Infectious Diseases, 6610 Rockledge Drive, Room 3025, Bethesda, MD 20892-6601
    • ,
  • Steven Z. Pavletic, MD

      Affiliations

    • Experimental Transplantation and Immunology Branch, National Cancer Institute, WG Magnuson Clinical Center, National Institutes of Health, Bethesda, MD
    • ,
  • Alan Tyndall, MD

      Affiliations

    • Department of Rheumatology, Felix Platter-Spital, Basel, Switzerland
    • ,
  • Alois Gratwohl, MD

      Affiliations

    • Department of Hematology, University Hospital Basel, Basel, Switzerland
    • ,
  • Daniel E. Furst, MD

      Affiliations

    • Rheumatology Division, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA
    • ,
  • Stephen J. Forman, MD

      Affiliations

    • Divisions of Hematology and Hematopoietic Cell Transplantation, and Medical Oncology and Therapeutics Research, City of Hope National Medical Center,Duarte, CA
    • ,
  • Richard A. Nash, MD

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

Received 9 February 2006 ,Accepted 10 February 2006.

References 

  1. Griffith LM , Pavletic SZ , Tyndall A , et al.   Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute—sponsored international workshop, Bethesda, MD. March 12 and 13, 2005 . Biol Blood Marrow Transplant . 2005;11:862–870
  2. Risitano AM , Maciejewski JP , Green S , Plasilova M , Zeng W , Young NS . In-vivo dominant immune responses in aplastic anemia (molecular tracking of putatively pathogenic T-cell clones by TCR beta-CDR3 sequencing) . Lancet . 2004;364:355–364
  3. Georges GE , Storb R . Allogeneic hematopoietic cell transplantation for aplastic anemia . In:  Blume KG ,  Forman SJ ,  Appelbaum FR editor. Thomas’ Hematopoietic Cell Transplantation . 3rd ed. Malden, MA: Blackwell Publishing; 2004;p. 981–1001
  4. Pediatric Diseases Working Party of the EBMT Stary J , Locatelli F , Niemeyer CM . Stem cell transplantation for aplastic anemia and myelodysplastic syndrome . Bone Marrow Transplant . 2005;35(suppl):S13–S16
  5. Hakim FT , Memon SA , Cepeda R , et al.   Age-dependent incidence, time course, and consequences of thymic renewal in adults . J Clin Invest . 2005;115:930–939
  6. Diaconescu R , Flowers CR , Storer B , et al.   Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors . Blood . 2004;104:1550–1558
  7. Thomas ED . The pros and cons of bone marrow transplantation for sickle cell anemia . Semin Hematol . 1991;28:260–262

PII: S1083-8791(06)00182-0

doi: 10.1016/j.bbmt.2006.02.007

Biology of Blood and Marrow Transplantation
Volume 12, Issue 6 , Pages 688-690 , June 2006

Article Tools